SCHEMBL752254

SCHEMBL752254

O=[N+]([O-])c1cc(Br)cc(F)c1O

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ERN1 O75460 1/20 0.59
GPR35 Q9HC97 4/20 0.48
TTR P02766 4/20 0.48
MEN1 O00255 2/20 0.48
ALDH1A1 P00352 2/20 0.48
MAPT P10636 2/20 0.48
KMT2A Q03164 2/20 0.48
KDM4E B2RXH2 1/20 0.48
CYP1A2 P05177 1/20 0.48
CYP2C9 P11712 1/20 0.48
HPGD P15428 1/20 0.48
ALOX15 P16050 1/20 0.48
ALOX12 P18054 1/20 0.48
MAPK1 P28482 1/20 0.48
RECQL P46063 1/20 0.48
PMP22 Q01453 1/20 0.48
HIF1A Q16665 1/20 0.48
HSD17B10 Q99714 1/20 0.48
TDP1 Q9NUW8 1/20 0.48
HTT P42858 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29674743 1.00 ERN1 (0.59) ERN1GPR35TTRMEN1ALDH1A1
SCHEMBL4144580 0.86 ERN1 (0.69) ERN1GPR35TTRMEN1ALDH1A1
SCHEMBL4167284 0.84 ERN1 (0.62) ERN1GPR35TTRMEN1ALDH1A1
SCHEMBL16654498 0.82 ERN1 (0.43) ERN1TTRMEN1ALDH1A1MAPT
SCHEMBL17699766 0.80 ERN1 (0.44) ERN1GPR35ALDH1A1MAPTCYP1A2
SCHEMBL29782441 0.80 ERN1 (0.44) ERN1GPR35ALDH1A1MAPTCYP1A2
SCHEMBL16005316 0.80 ERN1 (0.44) ERN1GPR35ALDH1A1MAPTCYP1A2
SCHEMBL2078816 0.80 TTR (0.57) GPR35TTRMEN1ALDH1A1MAPT
SCHEMBL7737429 0.80 ERN1 (0.62) ERN1GPR35TTRMEN1ALDH1A1
SCHEMBL7030693 0.80 CRHBP (0.58) ERN1GPR35TTRMEN1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 166 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260137706-A1 METHODS OF TREATING INFLAMMATORY DISEASES INTERLINE THERAPEUTICS INC (US) 2026-05-21 US disclosed
EP-4703359-A1 IMIDAZOPYRIDINE OR IMIDAZOPYRAZINE COMPOUND, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF Shanghai Simr Biotechnology Co., Ltd. (CN) 2026-03-04 EP disclosed
US-20250346593-A1 IMIDAZO(1,2-1)PYRIDINE DERIVATIVES AS RIPK2 INHIBITORS INTERLINE THERAPEUTICS INC (US) 2025-11-13 US disclosed
US-20250177408-A1 INHIBITOR OF INTERACTION BETWEEN YAP/TAZ AND TEAD, PREPARATION THEREOF, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF Etern Therapeutics Hongkong Limited (CN) 2025-06-05 US disclosed
EP-4561561-A2 SUBSTITUTED 3,4-DIHYDROQUINOLINONE INHIBITORS OF TSHR Septerna, Inc. (US) 2025-06-04 EP disclosed
US-20250171427-A1 THERAPEUTIC COMPOUNDS SANOFI (FR) 2025-05-29 US disclosed
WO-2025104230-A1 BENZOXAZOLES AS MODULATORS OF IL-17A SANOFI (FR) 2025-05-22 WO disclosed
CN-119698416-A Imidazo (1, 2-A) pyridine derivatives as RIPK2 inhibitors 英特莱治疗公司 2025-03-25 CN disclosed
EP-3704105-B9 ANTIBACTERIAL COMPOUNDS DISCUVA LTD (GB) 2025-03-05 EP disclosed
EP-4484420-A1 INHIBITOR OF INTERACTION BETWEEN YAP/TAZ AND TEAD, PREPARATION THEREOF, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF Etern Biopharma (Shanghai) Co., Ltd. (CN) 2025-01-01 EP disclosed
EP-1282621-A1 VITRONECTIN RECEPTOR ANTAGONISTS Aventis Pharma S.A. (FR) 2003-02-12 EP disclosed
CN-1355697-A IL-8 receptor antagonists SMITHKLINE BEECHAM CORP (US) 2002-06-26 CN disclosed
WO-2001085729-A1 NOVEL VITRONECTIN RECEPTOR ANTAGONISTS AVENTIS PHARMA S.A. (FR) 2001-11-15 WO disclosed
US-6262113-B1 HYDROXY- OR MERCAPTO-PHENYLUREAS SMITHKLINE BEECHAM CORPORATION 2001-07-17 US disclosed
EP-0757982-B1 Biphenylic compounds, process for their preparations and intermediates for this process, their use as 5-alpha-reductase inhibitors and pharmaceutical compositions containing them HOECHST MARION ROUSSEL INC (FR) 2000-09-20 EP disclosed
US-5965763-A Biphenyl compounds HOECHST MARION ROUSSEL (FR) 1999-10-12 US disclosed
CN-1215990-A IL-8 receptor antagonists SMITHKLINE BEECHAM CORP (US) 1999-05-05 CN disclosed
US-5827887-A 5-ALPHA REDUCTASE INHIBITORS ROUSSEL UCLAF (FR) 1998-10-27 US disclosed
EP-0757982-A1 Biphenylic compounds, process for their preparations and intermediates for this process, their use as 5-alpha-reductase inhibitors and pharmaceutical compositions containing them ROUSSEL UCLAF (FR) 1997-02-12 EP disclosed
US-4031249-A TREMATODES, NEMATODES, FASCIOLA SP ICI AUSTRALIA LIMITED (AU) 1977-06-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260137706-A1 METHODS OF TREATING INFLAMMATORY DISEASES NR3C1, CCR1, CXCR2 ERN1 1481/4885GPR35 2373/4885TTR 799/4885
US-20250346593-A1 IMIDAZO(1,2-1)PYRIDINE DERIVATIVES AS RIPK2 INHIBITORS RIPK2, RIPK1, RIPK4 ERN1 246/4885GPR35 3897/4885TTR 4634/4885
US-20250171427-A1 THERAPEUTIC COMPOUNDS IL17A, IL2, IL36G ERN1 3238/4885GPR35 620/4885TTR 1162/4885
US-20250177408-A1 INHIBITOR OF INTERACTION BETWEEN YAP/TAZ AND TEAD, PREPARATION THEREOF, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF YAP1, YES1, TEAD2 ERN1 2664/4885GPR35 4080/4885TTR 2115/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.